



Spectro+swiss



The 71st ASMS Conference, Houston, TX

Omnitrap-Orbitrap performance enhancement via unreduced data processing

Anton Kozhinov, Konstantin Nagornov, & Yury Tsybin


Spectroswiss, Lausanne, Switzerland

Conflict of interest: these co-authors are employees of Spectroswiss, which develops MS hardware & software

Camille Garcia, Martial Rey, Tingting Fu, & Julia Chamot-Rooke


Mass Spectrometry for Biology Unit, Institut Pasteur, Paris, France

Wednesday, June 7, 2023: WOA am Instrumentation: New Hybrid and Multimodal Approaches



Omnitrap-Orbitrap: A Multimodal MS/MS Platform


- **Omnitrap**: an add-on linear ion trap for the multimodal & multiple-stage tandem MS (MS/MS)
- Transforms the **HCD** (*b/y*-ions) Q Exactive & Exploris Orbitraps into versatile MS/MS platforms
- **ECD** (*c/z*-ions), electron ionization dissociation (**EID**), photo dissociation (**IR**, **UV**), **CID**, & more



Papanastasiou et al., JASMS, 2022, 33, 10, 1990–2007

Mohammed et al., DOI 10.1101/2023.05.15.540788

ECD and Activated-Ion ECD of Myoglobin (16.7 kDa)



Direct infusion
60 scans (1 us)
AGC 1e6
480k @ m/z 200



Exploris 480

Mohammed et al., DOI
10.1101/2023.05.15.540788


How to increase sequence coverage & confidence? The unreduced data!

Ion Signals in Orbitrap FTMS: Transients


- Ion identity (m/z) is encoded as a frequency of ion oscillations in an orbitrap
- Frequencies of ion oscillations are measured as time-domain signals (**transients**)

Three components to define a wave:

- Frequency
- Magnitude (measure of amplitude)
- Phase (angle)



- Example: two waves of the same frequency and amplitude, but different phase



Orbitrap Mass Spectra: aFT vs. eFT

- **Absorption FT (aFT)** preserves all information (f , A , phase), equal to transients = **unreduced**
- **Enhanced FT (eFT)** mass spectra in full or reduced profile (.RAW) = **reduced data**


unreduced data

reduced data


Desired: full profile aFT

Full profile eFT


Reduced profile eFT



$$\frac{S}{N} \sim \sqrt{n}$$



$$\frac{S}{N} < \sqrt{n}$$




$$\frac{S}{N} < \sqrt{n}$$

How to access the unreduced data?

Accessing the Unreduced Data from an Omnitrap-Orbitrap Platform

- Parallel transient acquisition via a high-performance external data acquisition (DAQ) system



Bleiner et al., JASMS 2020, 257-266

Marcus et al., JASMS 2021, 1224-1236


Exploris™ schematics: <https://planetorbitrap.com/>

Orbitrap - Omnitrap - FTMS Booster: A Powerful MS/MS Platform

Exploris 480 Set-Up

Karolinska Institute, Sweden


Roman Zubarev's Lab



Q Exactive HF Set-Up

Pasteur Institute, France

Julia Chamot-Rooke's Lab



FTMS Booster Provides **aFT Mass Spectra** via Phased Transients


transients






FT

aFT
mass
spectra

Regular




Phased



FTMS Booster Provides the Unreduced (Full) Transients


- Records ion signals from all ions, all the time they oscillate (decodes both start & **stop** triggers)
- Overheads are included into the transients: full and extended length transients (ultra-high res.)
- Ion accumulation + fragmentation times for scan N may exceed OT transient length for scan $N-1$



What benefits can we harvest by using the unreduced data?



Full Transients Benefits: Overheads

- Optimization of a 25 kDa mAb light chain ECD analysis on a Q Exactive HF - Omnitrap





$R = 15,000 @ m/z 200$

- RAW, eFT, Tacq = 32 ms
- H5, aFT (full), Tacq = 150 ms



$R = 120,000 @ m/z 200$


- RAW, eFT, Tacq = 256 ms
- H5, aFT, Tacq = 256 ms



Ubiquitin (8.6 kDa) Top-Down Analysis (ECD)


- Direct infusion ESI MS/MS for a total of 400 transients per experiment: similar outlook

1



Q Exactive Plus - Omnitrap
R = 70,000 @ m/z 200
transient length: 256 ms
reduced profile, eFT
spectral averaging
80 scans, **5 uscans**

2



Q Exactive Plus - Omnitrap
R = 70,000 @ m/z 200
transient length: 282 ms
full profile aFT
spectral averaging
400 scans, **1 uscan**

Ubiquitin Top-Down Analysis: 100% Sequence Coverage

1

eFT: 94.7 %, 243 fragments

N [M][Q][I][F][V][K][T][L][T][G] 10
 11 [K][T][I][T][L][E][V][E][P][S] 20
 21 [D][T][I][E][N][V][K][A][K][I] 30
 31 [Q][D][K][E][G][I][P][P][D][Q] 40
 41 [Q][R][L][I][F][A][G][K][Q][L] 50
 51 [E][D][G][R][T][L][S][D][Y][N] 60
 61 [I][Q][K][E][S][T][L][H][L][V] 70
 71 [L][R][L][R][G][G] C

2







aFT: 100.0 %, 317 fragments

N [M][Q][I][F][V][K][T][L][T][G] 10
 11 [K][T][I][T][L][E][V][E][P][S] 20
 21 [D][T][I][E][N][V][K][A][K][I] 30
 31 [Q][D][K][E][G][I][P][P][D][Q] 40
 41 [Q][R][L][I][F][A][G][K][Q][L] 50
 51 [E][D][G][R][T][L][S][D][Y][N] 60
 61 [I][Q][K][E][S][T][L][H][L][V] 70
 71 [L][R][L][R][G][G] C

- Abundant peaks lead to product ion detection in eFT & aFT

y_{76}^{8+} , 8559.617 Da (base peak)

c_{28}^{3+} , 3103.684 Da



Ubiquitin Top-Down Analysis: 100% Sequence Coverage

1

eFT: 94.7 %, 243 fragments



N [M][Q][I][F][V][K][T][L][T][G] 10
11 [K][T][I][T][L][E][V][E][P][S] 20
21 [D][T][I][E][N][V][K][A][K][I] 30
31 [Q][D][K][E][G][I][P][P][D][Q] 40
41 [Q][R][L][I][F][A][G][K][Q][L] 50
51 [E][D][G][R][T][L][S][D][Y][N] 60
61 [I][Q][K][E][S][T][L][H][L][V] 70
71 [L][R][L][R][G][G][C]

2

aFT: 100.0 %, 317 fragments


N [M][Q][I][F][V][K][T][L][T][G] 10
11 [K][T][I][T][L][E][V][E][P][S] 20
21 [D][T][I][E][N][V][K][A][K][I] 30
31 [Q][D][K][E][G][I][P][P][D][Q] 40
41 [Q][R][L][I][F][A][G][K][Q][L] 50
51 [E][D][G][R][T][L][S][D][Y][N] 60
61 [I][Q][K][E][S][T][L][H][L][V] 70
71 [L][R][L][R][G][G][C]

- The aFT data helps to detect the missing product ions



Ubiquitin Top-Down Analysis: Detecting More Product Ions

- aFT data shows enhanced sensitivity and dynamic range, particularly in the high mass range



eFT

aFT

LC-MS/MS Analysis: ECD of a mAb's Light Chain (25 kDa, 23+)

- Light chain extracted from the urine of patient with multiple myeloma
- Reduced light chain, QE HF, 1 LC-MS/MS run, **500** scans (1 uscan), 50 ms ECD, **10 ppm**

eFT

Sequence coverage: **78.0 %**

Total: 489; c - 163, z - 208, b - 27, y - 95

```
N [D L Q] [M T] [Q S] P [S T L S A] [S] V 15
16 G D [A V] [T] [L] T [C] R A S [Q S] [L] [N] 30
31 [V W L A W] [Y] [Q] Q K P G [K P] [P] [K] 45
46 L L L Y E [A] [S] [N] [L] [E] [S] [G] [V] [P] S 60
61 R [F] [S] [G] [S] [G] [S] G T E [F] T L T L 75
76 [S] [S] [L] [Q] [P] D [D] F [A] [T] [Y] Y [C] [Q] [Q] 90
91 [Y] [N] [S] [Y] [P] [Y] T F [G] [Q] [G] A [K] [L] [E] 105
106 [L] [K] [R] [T] V [A] A P [S] [V] [F] [L] [F] [P] [P] 120
121 [S] [D] [E] [Q] [L] [K] [S] [G] T [A] S V [V] [C] [L] 135
136 L [N] [N] [F] Y P [R] [E] [A] [K] [V] [Q] [W] [K] [V] 150
151 [D] [N] [A] [L] [Q] [S] [G] [N] [S] [Q] [E] [S] [V] T [E] 165
166 [Q] [D] [S] [K] [D] [S] T [Y] [S] [L] [S] [S] T L T 180
181 [L] [S] [K] [A] [D] [Y] [E] [K] [H] [K] L [Y] [A] [C] [E] 195
196 V [T] [H] [Q] G [L] [S] [S] [P] [V] T [K] [S] [F] [N] 210
211 R [G] E [C] C
```

aFT

Sequence coverage: **88.8%**


Total: 552; c - 201, z - 213, b - 48, y - 90

+10 %


```
N [D L Q] [M T] [Q] [S] P S T L S [A] [S] V 14
15 G [D A] [V] [T] [L] T [C] R A S [Q] [S] [L] [N] 29
30 V [W] [L A] [W] [Y] [Q] Q [K] [P] [G] [K] [P] [P] [K] 44
45 L [L] [L] Y E [A] [S] [N] [L] [E] [S] [G] [V] [P] [S] 59
60 R [F] [S] [G] [S] [G] [S] G T E F T L T L 74
75 [S] [S] [L] [Q] [P] D [D] F [A] [T] [Y] Y [C] [Q] [Q] 89
90 [Y] [N] [S] [Y] [P] Y T F [G] [Q] [G] A [K] [L] [E] 104
105 [L] [K] [R] [T] V [A] A P [S] [V] [F] [L] [F] [P] [P] 119
120 [S] [D] [E] [Q] [L] [K] [S] [G] T [A] S V V [C] [L] 134
135 L [N] [N] F Y P [R] [E] [A] [K] [V] [Q] [W] [K] [V] 149
150 [D] [N] [A] [L] [Q] [S] G [N] [S] [Q] [E] [S] [V] T [E] 164
165 [Q] [D] [S] [K] [D] [S] T [Y] [S] [L] [S] [S] T L T 179
180 [L] [S] [K] [A] [D] [Y] [E] [K] [H] [K] L [Y] [A] [C] [E] 194
195 V [T] [H] [Q] G [L] [S] [S] [P] [V] T [K] [S] [F] [N] 209
210 R [G] E [C] C
```



LC-MS/MS Analysis: ECD of a mAb's Light Chain (25 kDa, 23+)

- 5 LC-MS/MS runs (technical replicates), **2300** microscans total, **aFT** mass spectral averaging



1 replicate: Sequence coverage: **88.8%**
Total: 552; c - 201, z - 213, b - 48, y - 90


5 replicates: Sequence coverage: **90.7 %**
Total: 596; c - 220, z - 225, b - 48, y - 103








Sequence coverage is maximized for a given charge state – fragment another one

MS3/MS4 Workflows To Tackle S-S Bonds in Top-Down MS

- CID of an intact trastuzumab (49+), followed by ECD of its light chain (11+), & suppl. CID (9+..)





ECD of 11+ light chain (QE Plus)





Toward maximum sequence coverage in top-down MS

Ultra-High Resolution (Long Transients): Top-Down MS of a mAb



Trastuzumab, 150 kDa
Q Exactive Plus - Omnitrap
direct infusion, **CID**
 $R = 280,000$ @ m/z 200



Conclusions

- Novel MS/MS platforms, based on the **Omnitrap-Orbitrap-Booster** combination, have been developed on the basis of a Q Exactive Plus, a Q Exactive HF, and an Exploris 480 Orbitraps
- FTMS Boosters help to obtain the Orbitraps' **unreduced data**: transients and aFT spectra
- The **eFT** and aFT mass spectra are comparable for the same # & length transients (uscans)
- Benefits of the **unreduced data** on the employed Omnitrap-Orbitrap platforms:
 - reveal the Omnitrap's overheads: increased duty cycle and experiment optimization
 - offer parallel ion detection and fragmentation: interaction times (50-500 ms) in Omnitrap
 - main beneficial factors: longer transients and/or full profile (pos/neg) mass spectra
 - averaging the **aFT spectra** increases sensitivity and enhances protein **sequence coverage**
 - ultra-high resolution improves analysis of complex product ion distributions in top-down MS
- The **unreduced data** benefits other multimodal and hybrid MS/MS platforms, e.g., tribrids
- Outlook: use of a single ion counting (CDMS) to improve Omnitrap-Orbitrap workflows. CDMS benefits from **ultra-long transients** (25 s!) on a Q Exactive UHMR (WOA 2:50 PM, Heck *et al.*)

Maximizing MS/MS information output from the multimodal MS/MS platforms

